Sialic Acid Therapy and Siglec Modulation in CBS/PSP

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Sialic Acid Therapy and Siglec Modulation in CBS/PSP</th> </tr> <tr> <td class=“label”>Parameter</td> <td>Recommendation</td> </tr> <tr> <td class=“label”>Compound</td> <td>N-acetylneuraminic acid (Neu5Ac)</td> </tr> <tr> <td class=“label”>Dose</td> <td>500–1,000 mg/day</td> </tr> <tr> <td class=“label”>Form</td> <td>Powder or capsules</td> </tr> <tr> <td class=“label”>Timing</td> <td>With meals for tolerability</td> </tr> <tr> <td class=“label”>Monitoring</td> <td>CSF glycan profiling (emerging), cognitive assessments</td> </tr> <tr> <td class=“label”>Safety</td> <td>Generally well-tolerated; GI effects at high doses</td> </tr> <tr> <td class=“label”>Siglec</td> <td>Cell Type</td> </tr> <tr> <td class=“label”>CD33 (Siglec-3)</td> <td>Microglia</td> </tr> <tr> <td class=“label”>Siglec-9</td> <td>Microglia, neutrophils</td> </tr> <tr> <td class=“label”>Siglec-11</td> <td>Microglia</td> </tr> <tr> <td class=“label”>Siglec-6</td> <td>Neurons</td> </tr> <tr> <td class=“label”>Therapy</td> <td>Dose</td> </tr> <tr> <td class=“label”>N-acetylneuraminic acid</td> <td>500–1,000 mg/day oral</td> </tr> <tr> <td class=“label”>O-GlcNAcylation optimization</td> <td>Diet, exercise, GLP-1</td> </tr> <tr> <td class=“label”>FNP-223 (if available)</td> <td>As per trial protocol</td> </tr> <tr> <td class=“label”>GM1 ganglioside</td> <td>IV/intranasal (under study)</td> </tr> <tr> <td class=“label”>PSA-NCAM mimetics</td> <td>Under development</td> </tr> <tr> <td class=“label”>Target</td> <td>Approach</td> </tr> <tr> <td class=“label”>CD33 antagonists</td> <td>Antibody-based</td> </tr> <tr> <td class=“label”>Siglec-9 modulators</td> <td>Small molecule</td> </tr> <tr> <td class=“label”>PSA mimetics</td> <td>Peptide/glycopeptide</td> </tr> <tr> <td class=“label”>Sialidase inhibitors</td> <td>Small molecule</td> </tr> <tr> <td class=“label”>GNE modulators</td> <td>Increase endogenous synthesis</td> </tr> </table>

Sialic acid therapy represents an emerging therapeutic strategy for 4R-tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Sialic acids are nine-carbon monosaccharides that terminate glycan chains on proteins and lipids, playing critical roles in cell-cell recognition, immune regulation, and synaptic function[@duran2024]. This page covers four interconnected therapeutic approaches: oral sialic acid supplementation, Siglec receptor modulation, polysialic acid (PSA)-mediated neural repair, and the relationship to O-GlcNAcylation (tau’s competing post-translational modification).

For comprehensive coverage of the broader glycobiology landscape, see the Glycomics Therapy CBS/PSP page covering glycan profiling technologies, ganglioside therapy, and N-of-1 personalized glycan-guided approaches.

1. Sialic Acid Biology and Deficiency in Tauopathies

1.1 Sialic Acid Structure and Function

Sialic acids are derivatives of N-acetylneuraminic acid (Neu5Ac), the most common sialic acid in humans. They terminate the non-reducing ends of N-linked and O-linked glycans on glycoproteins, gangliosides, and proteoglycans, serving as critical determinants of cellular identity and function[@crocker2007].

Key functions in the CNS:

Synaptic regulation: Sialylated receptors modulate neurotransmitter signaling and synaptic plasticity
Immune evasion: Siglec receptors on microglia recognize sialylated self structures, maintaining immune tolerance
Membrane protection: Sialic acid residues protect glycoproteins from proteolysis and maintain membrane stability
Cellular recognition: Sialylated structures mediate neuron-glia interactions and axonal guidance

1.2 Sialic Acid Deficiency in CBS/PSP

Evidence indicates that sialic acid metabolism is dysregulated in 4R-tauopathies:

CSF sialic acid levels are reduced in PSP patients compared to healthy controls[@westbrandt2023]
Neuronal sialylation declines with age and accelerates in neurodegeneration
Elevated sialidase (neuraminidase) activity in tauopathy brains may drive pathological desialylation
Reduced ganglioside sialylation in post-mortem PSP brain tissue correlates with disease severity[@sonnino2024]
O-GlcNAcylation deficits in tauopathy brains result from impaired glucose metabolism, reducing tau’s protective glycosylation[@yuzwa2024]

This creates a self-reinforcing cycle: reduced sialic acid leads to compromised membrane integrity and altered immune signaling, while decreased O-GlcNAcylation allows unchecked tau phosphorylation.

2. Oral Sialic Acid Supplementation

2.1 Rationale

Oral N-acetylneuraminic acid supplementation aims to:

Increase systemic sialic acid availability for incorporation into gangliosides and glycoproteins
Support proper protein glycosylation throughout the CNS
Counteract elevated sialidase activity by providing substrate excess
Enhance microglial Siglec activation for anti-inflammatory signaling

2.2 Evidence

Animal studies demonstrate cognitive benefit from oral Neu5Ac supplementation[@galeano2022]. Mechanistically, sialic acid crosses the blood-brain barrier to some extent, and increasing peripheral sialic acid availability supports CNS sialylation through the salvage pathway.

2.3 Clinical Approach

Combining with glucose management: O-GlcNAcylation requires glucose as a substrate. Patients with impaired glucose uptake may benefit from concurrent metabolic optimization (see Ketogenic Diet) to increase substrate availability for O-GlcNAc transferase (OGT).

2.4 Precursor Loading Strategy

An alternative approach uses N-acetylmannosamine (ManNAc), a sialic acid precursor, to increase endogenous sialic acid synthesis through the GNE pathway. This may produce more sustained elevation in sialic acid levels.

3. Siglec Receptor Modulation

3.1 Siglec Biology

Siglecs (sialic acid-binding immunoglobulin-type lectins) are a family of cell surface receptors that recognize sialic acid-containing structures[@crocker2007]. In the CNS, key Siglecs include:

3.2 CD33 in Tauopathy

CD33 is expressed on microglia and functions as an inhibitory receptor that regulates phagocytosis. GWAS identified CD33 as an Alzheimer’s disease risk gene — the CD33 risk allele is associated with:

Increased CD33 expression on microglia
Reduced Aβ clearance
Enhanced neuroinflammation

Anti-CD33 antibodies have demonstrated reduced amyloid plaque burden in mouse models[@bhattacharjee2022]. While primarily studied in AD, CD33 also regulates microglial responses to tau pathology.

Therapeutic approaches for CD33:

Anti-CD33 monoclonal antibodies (under development for AD)
Siglec-engineered fusion proteins
Sialic acid mimetics that engage CD33 signaling

3.3 Siglec-9 Targeting

Siglec-9 is a bifunctional receptor — it can both inhibit and activate depending on context. In neurodegeneration, Siglec-9 appears to drive pro-inflammatory responses when activated by specific sialic acid patterns. Novel Siglec-9 antagonists are in preclinical development for neuroinflammatory conditions.

3.4 Siglec Agonism vs Antagonism

The therapeutic strategy depends on the specific Siglec:

CD33: Antagonism/inhibition may enhance microglial clearance of pathological proteins
Siglec-9: Agonism may suppress neuroinflammatory microglial phenotypes
Siglec-11: Agonism is neuroprotective

4. Polysialic Acid (PSA) and Neural Plasticity

4.1 PSA-NCAM Biology

Polysialic acid is a linear polymer of Neu5Ac attached to neural cell adhesion molecule (NCAM). PSA-NCAM is highly expressed during brain development, where it promotes neural plasticity by reducing cell adhesion and allowing synaptic remodeling[@rutkowski2023].

In the adult brain, PSA-NCAM expression is restricted to regions of ongoing neurogenesis (hippocampus subgranular zone, subventricular zone) and to areas with high plasticity. Notably:

PSA levels decline with aging
PSA-NCAM+ neurons show enhanced survival and integration
PSA modulates neuroinflammation through Siglec interactions

4.2 Therapeutic Potential in CBS/PSP

Enhancing neural plasticity: Administering PSA or PSA-NCAM mimetics may support remaining neuronal circuits in CBS/PSP by promoting synaptic remodeling and functional compensation.

Delivery approaches:

Intranasal delivery of PSA-NCAM mimetics (bypasses BBB)
Exogenous PSA administration to increase CNS availability
Small molecule NCAM mimetics that trigger PSA-like signaling

Combination with exercise: Physical activity upregulates PSA-NCAM expression in the hippocampus. Combining PSA supplementation with high-intensity exercise may synergistically enhance neuroplasticity.

5. O-GlcNAcylation — The Glycosylation-Phosphorylation Battle

5.1 Tau O-GlcNAcylation

Tau protein is modified by O-linked N-acetylglucosamine (O-GlcNAc) at serine and threonine residues. This modification is mutually exclusive with phosphorylation — a site that is O-GlcNAcylated cannot be phosphorylated, and vice versa[@yuzwa2024].

Key facts:

O-GlcNAcylated tau is less likely to aggregate
O-GlcNAcylation promotes tau solubility and prevents toxic oligomer formation
Brain glucose uptake is impaired in CBS/PSP, reducing O-GlcNAc levels
The O-GlcNAc/phosphorylation balance is shifted toward hyperphosphorylation in tauopathies

5.2 OGA Inhibition (FNP-223)

O-linked N-acetylglucosaminidase (OGA) is the enzyme that removes O-GlcNAc from proteins. OGA inhibitors (such as FNP-223, which is in Phase 2 for PSP) increase tau O-GlcNAcylation, competing with pathological phosphorylation.

FNP-223 for CBS/PSP:

PROSPER Phase 2 completed recruitment (220 patients, October 2025)
Novel mechanism distinct from anti-tau antibodies
Results expected 2026
See FNP-223 OGA Inhibitor for full details

Note: OGA inhibition is not sialic acid therapy per se, but falls under the broader glycobiology umbrella of targeting tau post-translational modifications through glycan-based approaches.

5.3 Glucose Metabolism Optimization

Since O-GlcNAcylation requires glucose, strategies to improve CNS glucose metabolism may naturally increase tau O-GlcNAcylation:

Ketogenic diet (reduces glucose dependence)
Exercise (improves insulin sensitivity)
GLP-1 agonists (may enhance glucose metabolism)
Avoiding prolonged hypoglycemia

6. Ganglioside Therapy

6.1 Gangliosides in CBS/PSP

Gangliosides are sialic acid-containing glycosphingolipids enriched in neuronal membranes. The major CNS gangliosides (GM1, GD1a, GT1b, GQ1b) regulate synaptic function, neurotrophin signaling, and membrane integrity.

In CBS/PSP:

GM1 and GD1a levels are reduced in post-mortem tauopathy brains[@sonnino2024]
Ganglioside loss correlates with neuronal dysfunction and synaptic loss
GM1 administration in animal models shows neuroprotective effects

See Gangliosides in Neurodegeneration for detailed coverage.

6.2 GM1 Ganglioside Therapy

GM1 ganglioside has been tested clinically in Parkinson’s disease and stroke:

Neurotrophic and neuroprotective effects in preclinical models
GM1 therapy trials in PD showed modest motor improvement
Potential for CBS/PSP given shared neurodegenerative mechanisms

Delivery: Intravenous or intranasal administration. Intranasal delivery may reduce the risk of anti-GM1 antibody formation observed with long-term parenteral use.

6.3 Siglec-Ganglioside Interactions

Gangliosides serve as ligands for Siglec receptors on microglia. Sialylated gangliosides (GM1, GD1a) engage Siglec receptors to modulate microglial activation. Restoring ganglioside levels may therefore:

Provide direct neurotrophic support
Enhance Siglec-mediated anti-inflammatory signaling

7. Clinical Implementation for CBS/PSP

7.1 Personalized Approach

Sialic acid therapy should be personalized based on:

CSF glycan profiling (emerging biomarker)
Serum sialic acid levels
O-GlcNAcylation status (CSF or imaging biomarkers)
Ganglioside patterns in accessible tissues

7.2 Integrated Protocol

7.3 Drug Interactions

No significant interactions with levodopa or rasagiline
May enhance absorption of co-administered therapies via glycan-mediated transport
Combining with glucose management optimizes O-GlcNAcylation capacity

7.4 Monitoring

Cognitive and motor assessments every 3–6 months
NfL and p-tau217 as progression biomarkers
CSF glycan profiling when available (research setting)
MRI volumetrics for atrophy tracking

8. Research Pipeline and Future Directions

Emerging Targets

Clinical Trials to Watch

FNP-223 PROSPER (Phase 2, PSP, results 2026) — primary OGA inhibitor trial
Siglec-targeted antibodies (when they enter neurodegeneration trials)

9. Related Pages

Glycomics Therapy CBS/PSP — Comprehensive glycobiology coverage
CD33 Modulation Therapy — Microglial CD33 targeting
Gangliosides in Neurodegeneration — Membrane lipid biology
FNP-223 OGA Inhibitor — O-GlcNAcylation enhancement via OGA inhibition
O-GlcNAcylation and Tau Pathology — Glycosylation-phosphorylation interplay
Gasotransmitters in Neuroprotection — Related emerging mechanisms